Date added: 20/06/2017 Australia Japan Foundation - Children's Cancer Institute (Chang)


Australia Japan Foundation Initiative - Children's Cancer Institute (Chang)

CCI Logo

Dr David Chang from the Children’s Cancer Institute Australia (CCIA, NSW) received a cell line which was funded under the Australia-Japan foundation initiative for his work in cancer therapeutics and diagnostics research using iron oxide nanoparticles in prostate cancer. He described his project below.

"Iron oxide organic and inorganic composites for a two pronged approach to cancer therapy.

Magnetic iron oxide nanoparticles have the potential to improve the outcomes of patients with prostate cancer. Due to their magnetic properties, magnetic iron oxide nanoparticles can act as a contrast agent for MRI and induce localized heating under an alternating magnetic field, potentially leading to cancer cell death. Furthermore, iron oxide nanoparticles have been shown to be radiosensitizing when internalized by cancer cells by elevating reactive oxygen species levels through the Fenton reaction.

The aim of the research project is to develop an effective theranostic iron oxide nanoparticle which can improve the outcomes in patients with prostate cancer. As part of my PhD program, I will develop and characterize iron oxide nanoparticles conjugated to prostate specific membrane antigen (PSMA) ligand that targets PSMA expressing prostate cancer cells. Then, the nanoparticles will be applied to PSMA -ve and PSMA +ve prostate cancer cell lines in order to determine the uptake and the impact of combining irradiation and an alternating magnetic field. Subsequently, I will evaluate the distribution and therapeutic effects of PSMA targeting iron oxide nanoparticles in vivo."

Dr Chang chose a luciferase-expressed cell line (PMSA negative) from the Japanese repository JCRB to also be able to monitor the tumour in mouse models in comparison with PSMA expressing prostate cancer cell lines.

Australia Japan Foundation Logo

"Japan-derived cell-lines for Australia-based preclinical Non-Communicable Disease (NCD) research” is supported by the Australian Government through the Australia-Japan Foundation of the Department of Foreign Affairs and Trade.